AIM: To optimize formulation methods for loading gemcitabine (GEM), the main drug against pancreatic cancer, into albumin nanoparticles for extended blood circulation and improved efficacy. METHODS: GEM was loaded into two sizes of disolvation-crosslinked bovine serum albumin nanoparticles, with a mean diameter of 109.7 nm and 405.6 nm, respectively, by co-precipitation (the direct method) and follow-up adsorption (the indirect method). The antitumor activities of the two nanoparticulate formulations, were evaluated according to their anti-proliferative effects on the human pancreatic cell line BXPC-3, which were assessed using the MTT assay. RESULTS: The two nanoparticulate formulations, created by direct co-precipitation and indirect adsorption, possessed smooth surfaces and high drug loading efficiencies, 83% and 93% at 11% and 13% drug loading, respectively. The two formulations released GEM for 8 and 12 h, respectively, and significantly improved anti-BXPC-3 proliferation effects, as compared with the GEM solution and the drug-free albumin particles. CONCLUSION: Co-precipitating and adsorbing GEM into albumin particles resulted in sustained-release nanoparticulate formulations with improved antitumor cytotoxicity. The result suggests that this is a useful formulation strategy for improving the antitumor efficacy of GEM.
AIM: To optimize formulation methods for loading gemcitabine (GEM), the main drug against pancreatic cancer, into albumin nanoparticles for extended blood circulation and improved efficacy. METHODS:GEM was loaded into two sizes of disolvation-crosslinked bovine serum albumin nanoparticles, with a mean diameter of 109.7 nm and 405.6 nm, respectively, by co-precipitation (the direct method) and follow-up adsorption (the indirect method). The antitumor activities of the two nanoparticulate formulations, were evaluated according to their anti-proliferative effects on the humanpancreatic cell line BXPC-3, which were assessed using the MTT assay. RESULTS: The two nanoparticulate formulations, created by direct co-precipitation and indirect adsorption, possessed smooth surfaces and high drug loading efficiencies, 83% and 93% at 11% and 13% drug loading, respectively. The two formulations released GEM for 8 and 12 h, respectively, and significantly improved anti-BXPC-3 proliferation effects, as compared with the GEM solution and the drug-free albumin particles. CONCLUSION: Co-precipitating and adsorbing GEM into albumin particles resulted in sustained-release nanoparticulate formulations with improved antitumor cytotoxicity. The result suggests that this is a useful formulation strategy for improving the antitumor efficacy of GEM.
Authors: H Hashizume; P Baluk; S Morikawa; J W McLean; G Thurston; S Roberge; R K Jain; D M McDonald Journal: Am J Pathol Date: 2000-04 Impact factor: 4.307
Authors: Makan Khoshnejad; Vladimir V Shuvaev; Katherine W Pulsipher; Chuanyun Dai; Elizabeth D Hood; Evguenia Arguiri; Melpo Christofidou-Solomidou; Ivan J Dmochowski; Colin F Greineder; Vladimir R Muzykantov Journal: Bioconjug Chem Date: 2016-01-15 Impact factor: 4.774
Authors: Kevin O Affram; Taylor Smith; Edward Ofori; Sunil Krishnan; Patrick Underwood; Jose G Trevino; Edward Agyare Journal: J Drug Deliv Sci Technol Date: 2019-11-08 Impact factor: 3.981
Authors: Lauren J Delaney; John R Eisenbrey; David Brown; Jonathan R Brody; Masaya Jimbo; Brian E Oeffinger; Maria Stanczak; Flemming Forsberg; Ji-Bin Liu; Margaret A Wheatley Journal: Acta Biomater Date: 2021-05-31 Impact factor: 10.633
Authors: Nimil Sood; Walter T Jenkins; Xiang-Yang Yang; Nikesh N Shah; Joshua S Katz; Cameron J Koch; Paul R Frail; Michael J Therien; Daniel A Hammer; Sydney M Evans Journal: J Pharm (Cairo) Date: 2013